709665-73-6

Basic information

• Product Name: (4-Bromophenyl)-tert-butoxycarbonylaminoacetic acid methyl ester
• Synonyms: (4-BROMO-PHENYL)-TERT-BUTOXYCARBONYLAMINO-ACETIC ACID METHYL ESTER;Methyl 2-(4-broMophenyl)-2-{[(tert-butoxy)carbonyl]aMino}acetate;Methyl 2-((4-broMophenyl)(tert-butoxycarbonyl)aMino)acetate;Methyl 2-(Boc-amino)-2-(4-bromophenyl)acetate
• CAS NO: 709665-73-6
• Molecular Formula: C₁₄H₁₈BrNO₄
• Molecular Weight: 344.2
• Mol File: 709665-73-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 385.4 °C at 760 mmHg
• Flash Point: 186.9 °C
• Appearance: /
• Density: 1.382 g/cm³
• Refractive Index: 1.538
• Storage Temp.: 2-8°C
• PKA: 10.53±0.46(Predicted)
• CAS DataBase Reference: (4-Bromophenyl)-tert-butoxycarbonylaminoacetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Bromophenyl)-tert-butoxycarbonylaminoacetic acid methyl ester(709665-73-6)
• EPA Substance Registry System: (4-Bromophenyl)-tert-butoxycarbonylaminoacetic acid methyl ester(709665-73-6)

Safety Data

• Hazardous Substances Data: 709665-73-6(Hazardous Substances Data)

Usage

General Description

(4-Bromophenyl)-tert-butoxycarbonylaminoacetic acid methyl ester is a chemical compound with the molecular formula C14H18BrNO4. It is an ester derivative of a tert-butoxycarbonyl (Boc)-protected amino acid, containing a bromophenyl group. (4-Bromophenyl)-tert-butoxycarbonylaminoacetic acid methyl ester is commonly used in organic synthesis as a building block for the preparation of complex organic molecules. It can serve as a precursor for the synthesis of various pharmaceuticals and agrochemicals. Additionally, it is important in medicinal chemistry research as a potential lead compound for the development of new drugs. Overall, (4-Bromophenyl)-tert-butoxycarbonylaminoacetic acid methyl ester has significant applications in the field of organic chemistry and drug discovery.

InChI:InChI=1/C14H18BrNO4/c1-13(2,3)20-12(18)14(16,11(17)19-4)9-5-7-10(15)8-6-9/h5-8H,16H2,1-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 917925-71-4 2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)acetic acid 
• 74-88-4 methyl iodide 
• 119397-06-7 2-amino-2-(4-bromophenyl)acetic acid 
• 42718-15-0 methyl 2-amino-2-(4-bromophenyl)acetate 

Downstream Products

• 369403-44-1 2-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)acetic acid 

Relevant articles and documents

A Structure?Activity Relationship Study of Novel Hydroxamic Acid Inhibitors around the S1 Subsite of Human Aminopeptidase N

Aminopeptidase N (APN/CD13) is a zinc-dependent ubiquitous transmembrane ectoenzyme that is widely present in different types of cells. APN is one of the most extensively studied metalloaminopeptidases as an anti-cancer target due to its significant role in the regulation of metastasis and angiogenesis. Previously, we identified a potent and selective APN inhibitor, N-(2-(Hydroxyamino)-2-oxo-1-(3′,4′,5′-trifluoro-[1,1′-biphenyl]-4-yl)ethyl)-4-(methylsulfonamido)benzamide (3). Herein, we report the further modifications performed to explore SAR around the S1 subsite of APN and to improve the physicochemical properties. A series of hydroxamic acid analogues were synthesised, and the pharmacological activities were evaluated in vitro. N-(1-(3′-Fluoro-[1,1′-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)-4-(methylsulfonamido)benzamide (6 f) was found to display an extremely potent inhibitory activity in the sub-nanomolar range.

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B. Specifically, provided herein is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions

Malaria remains a global health problem, and though international efforts for treatment and eradication have made some headway, the emergence of drug-resistant parasites threatens this progress. Antimalarial therapeutics acting via novel mechanisms are urgently required. Plasmodium falciparum M1 and M17 are neutral aminopeptidases which are essential for parasite growth and development. Previous work in our group has identified inhibitors capable of dual inhibition of PfA-M1 and PfA-M17, and revealed further regions within the protease S1 pockets that could be exploited in the development of ligands with improved inhibitory activity. Herein, we report the structure-based design and synthesis of novel hydroxamic acid analogues that are capable of potent inhibition of both PfA-M1 and PfA-M17. Furthermore, the developed compounds potently inhibit Pf growth in culture, including the multi-drug resistant strain Dd2. The ongoing development of dual PfA-M1/PfA-M17 inhibitors continues to be an attractive strategy for the design of novel antimalarial therapeutics.